MelMarT-II – update.

There are now several sites open and as of the beginning of December 2021, there are over 500 patients enrolled internationally. 

Melanoma UK was involved in the interview process for the new clinical trial coordinator and we are very pleased to announce that the role has now been filled.  Details of the new coordinator will be announced very soon.

Information relating to participation and eligibility is as follows:

Participants must be over 18 years of age

Participants  will already have a Stage 2 primary invasive cutaneous melanoma.  This might be, head, arms, legs, body, scalp, limbs.  (Note, there will be some areas that will be excluded)

There must have been no previous surgeries to remove this melanoma.


The MelMarT-II study is a randomised study which will determine whether there is a difference in local recurrence rates and melanoma survival rates for patients treated with either a 1cm excision margin or 2cm margin for both intermediate and high risk melanomas.

The study is designed to be able to prove or disprove that there is no difference in risk of the tumour recurring around the scar or anywhere else in the body between the two groups of patients.

This study is designed to show that the risk of long-term pain associated with surgery can be halved. If the study shows no risk of the tumour recurrence, then we will also be able to determine how much of an impact the narrower excision has on patients in terms of improved quality of life and reduced side effects from the surgery and melanoma disease.

This trial will also evaluate and determine the economic impact of narrower excision margins on the health services and society in general


(** If you think you are eligible for this trial, please speak to the team/clinician who is responsible for your care)